BARD1 Gene Polymorphisms Confer Nephroblastoma Susceptibility

BRCA1-associated RING domain protein 1 (BARD1) is a tumor suppressor, which forms a heterodimer with BRCA1. Three BARD1 gene polymorphisms (rs7585356 G > A, rs6435862 T > G and rs3768716 A > G) were initially identified as high-risk neuroblastoma susceptibility loci by a previous GWAS. Because of the general tumor-suppressing function of BARD1, we hypothesized that these BARD1 gene polymorphisms might modify the susceptibility to nephroblastoma. We genotyped these polymorphisms in 145 cases and 531 controls using Taqman methods. Out of three polymorphisms, only the rs7585356 G > A polymorphism was significantly associated with increased susceptibility to nephroblastoma [AA vs. GG: adjusted odds ratio (OR) = 1.78, 95% confidence interval (CI) = 1.01–3.12]. Combined analysis of three polymorphisms indicated that subjects with 3 risk genotypes exhibited significantly elevated nephroblastoma risk, when compared with subjects with 0–2 risk genotypes (adjusted OR = 1.72, 95% CI = 1.02–2.89). Stratified analysis revealed that in term of clinical stage, rs7585356 AA carriers were associated with increased risk of developing clinical stage I + II nephroblastoma. The presence of three risk genotypes was significantly associated with nephroblastoma risk in females and clinical stage I + II nephroblastoma. Our results suggested that BARD1 rs7585356 G > A may be associated with nephroblastoma risk.

[1]  H. Xia,et al.  The Association between GWAS-identified BARD1 Gene SNPs and Neuroblastoma Susceptibility in a Southern Chinese Population , 2016, International journal of medical sciences.

[2]  Hua Tan,et al.  Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity , 2015, Scientific Reports.

[3]  M. Ritchey,et al.  Current management of Wilms' tumor in children. , 2009, Journal of pediatric urology.

[4]  M. Cevher,et al.  DNA damage-induced BARD1 phosphorylation is critical for the inhibition of messenger RNA processing by BRCA1/BARD1 complex. , 2006, Cancer research.

[5]  Hongbing Shen,et al.  Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis. , 2009, Gynecologic oncology.

[6]  I. Irminger-Finger,et al.  New concepts on BARD1: Regulator of BRCA pathways and beyond. , 2016, The international journal of biochemistry & cell biology.

[7]  Nazneen Rahman,et al.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma , 2009, Nature Genetics.

[8]  H. Xia,et al.  Potentially functional polymorphisms in the LIN28B gene contribute to neuroblastoma susceptibility in Chinese children , 2016, Journal of cellular and molecular medicine.

[9]  K. Pritchard-Jones,et al.  Wilms' tumor: biology, diagnosis and treatment. , 2014, Translational pediatrics.

[10]  Menghong Sun,et al.  Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations , 2012, Human Genetics.

[11]  R. Greenberg,et al.  Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. , 2006, Genes & development.

[12]  T. Ludwig,et al.  Loss of Bard1, the Heterodimeric Partner of the Brca1 Tumor Suppressor, Results in Early Embryonic Lethality and Chromosomal Instability , 2003, Molecular and Cellular Biology.

[13]  H. Xia,et al.  Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population , 2016, Journal of cellular and molecular medicine.

[14]  T. Ohta,et al.  The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation* , 2001, The Journal of Biological Chemistry.

[15]  H. Ruffner,et al.  Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Katagiri,et al.  Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. , 2006, Human molecular genetics.

[17]  Q. Wei,et al.  Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population , 2016, Journal of cellular and molecular medicine.

[18]  J. Gulcher,et al.  The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland , 2006, PLoS medicine.

[19]  Heli Nevanlinna,et al.  BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition , 2006, European Journal of Human Genetics.

[20]  J. Dome,et al.  Wilms Tumor Predisposition , 2016 .

[21]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[22]  M. King,et al.  Mapping the Functional Domains of BRCA1 , 1999, The Journal of Biological Chemistry.

[23]  Wen-li Ma,et al.  Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls , 2011, Journal of Cancer Research and Clinical Oncology.

[24]  A. Horwitz,et al.  BRCA1 DNA-binding activity is stimulated by BARD1. , 2006, Cancer research.

[25]  M. King,et al.  BRCA1 RING Domain Cancer-predisposing Mutations , 2001, The Journal of Biological Chemistry.

[26]  H. Xia,et al.  LMO1 gene polymorphisms contribute to decreased neuroblastoma susceptibility in a Southern Chinese population , 2016, Oncotarget.

[27]  C. Jefford,et al.  Is there more to BARD1 than BRCA1? , 2006, Nature Reviews Cancer.

[28]  H. Xia,et al.  Evaluation of GWAS-identified SNPs at 6p22 with neuroblastoma susceptibility in a Chinese population , 2016, Tumor Biology.

[29]  Hongbing Shen,et al.  Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis , 2007, Breast Cancer Research and Treatment.

[30]  H. Xia,et al.  Lack of Associations between XPC Gene Polymorphisms and Neuroblastoma Susceptibility in a Chinese Population , 2016, BioMed research international.

[31]  Ying Zheng,et al.  [Recent incidences and trends of childhood malignant solid tumors in Shanghai, 2002-2010]. , 2013, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[32]  Laurent Briollais,et al.  SNP-SNP interactions in breast cancer susceptibility , 2006, BMC Cancer.

[33]  Q. Wei,et al.  Associations of PI3KR1 and mTOR Polymorphisms with Esophageal Squamous Cell Carcinoma Risk and Gene-Environment Interactions in Eastern Chinese Populations , 2015, Scientific Reports.

[34]  Jeremy M. Stark,et al.  Genetic Steps of Mammalian Homologous Repair with Distinct Mutagenic Consequences , 2004, Molecular and Cellular Biology.

[35]  H. Hakonarson,et al.  Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. , 2013, Carcinogenesis.

[36]  Y. Labrie,et al.  Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian Families with high risk of breast cancer , 2009, Journal of Human Genetics.

[37]  X. Zhang,et al.  Association of three common BARD1 variants with cancer susceptibility: a system review and meta-analysis. , 2015, International journal of clinical and experimental medicine.

[38]  Katia Basso,et al.  The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression , 2008, Proceedings of the National Academy of Sciences.

[39]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.